Metagenomi Therapeutics (MGX) Q2 2026 earnings summary

Executive summary

• Focused on in vivo genome editing using proprietary CRISPR-based tools and AI, with a strategic pipeline reprioritization in late 2025.

• Lead program MGX-001 targets hemophilia A, showing curative preclinical results, with IND submission planned for Q4 2026 and clinical trial initiation in 2027.

• Engaged with key opinion leaders and hemophilia investigators to prepare for first-in-human studies; MGX-001 preclinical data recognized at the 2026 ISTH Congress.

• Collaboration with Ionis Pharmaceuticals continues, with four Wave 1 targets in cardiometabolic indications in lead optimization.

Financial highlights

• Collaboration revenue was $(0.3) million for Q2 2026, down from $8.5 million in Q2 2025, due to a $2.6 million cumulative catch-up adjustment and lower Ionis-related revenue.

• Net loss for Q2 2026 was $27.5 million, compared to $19.9 million in Q2 2025; net loss per share was $(0.73) versus $(0.54) prior year.

• Operating expenses for Q2 2026 were $28.5 million, slightly down from $29.5 million in Q2 2025; R&D expenses were $22.5 million, unchanged year-over-year; G&A expenses decreased to $6.0 million from $7.0 million.

• Cash, cash equivalents, and available-for-sale marketable securities totaled $120.7 million as of June 30, 2026.

Outlook and guidance

• Cash runway expected to support operations for at least the next 12 months and through Q4 2027.

• IND-enabling studies for MGX-001 expected to complete by end of Q3 2026; IND submission planned for Q4 2026, with clinical trials anticipated in 2027.

• Substantial additional funding will be required to advance programs into clinical development and commercialization.

• No revenue from product sales is expected for the foreseeable future; focus remains on advancing preclinical and clinical pipeline.